A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.
At the conclusion of this course, participants will be able to:
- Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
- Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice
- Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
- Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT
With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era. New diagnostic and therapeutic agents with remarkable sensitivity and specificity are revolutionizing Nuclear Medicine and Oncology. This course will highlight the latest targeted imaging agents for neuroendocrine and prostate cancers (Ga-68 DOTATATE and Ga-68 PSMA PET/CT) as well as review important core concepts in PET/CT imaging and therapeutic Nuclear Medicine.
Time: 07:30 to 17:45
Practicing Physician/Industry: USD 1295.00,
Resident/Fellow/Technologist/RN/PA/RRA: USD 995.00
Speakers: Andy Quon, MD, Johannes Czernin, MD, Don Yoo, MD